XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Price Passes Below 200-Day Moving Average – What’s Next?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.67 and traded as low as $2.43. XTL Biopharmaceuticals shares last traded at $2.4550, with a volume of 1,829 shares.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

XTL Biopharmaceuticals Price Performance

The stock has a market cap of $5.82 million, a P/E ratio of -3.84 and a beta of 1.38. The stock’s 50-day moving average is $2.77 and its two-hundred day moving average is $2.67.

XTL Biopharmaceuticals (NASDAQ:XTLB) last announced its quarterly earnings results on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of ($0.26) million for the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.